Author:
Weiner Adam B.,Agrawal Raag,Valle Luca F.,Sonni Ida,Kishan Amar U.,Rettig Matthew B.,Raman Steven S.,Calais Jeremie,Boutros Paul C.,Reiter Robert E.
Funder
Simon-Strauss Foundation
UCLA Dr. Allen and Charlotte Ginsburg Fellowship in Precision Genomic Medicine
Prostate Cancer Foundation Young Investigator Award
National Institutes of Health
Office of Extramural Research, National Institutes of Health
National Institutes of Health,United States
U.S. Department of Defense
U.S. Department of Defense,United States
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Oncology
Reference82 articles.
1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA A Cancer J Clin. 2021;71:209–49.
2. Horoszewicz JS, Kawinski E, Murphy GP. Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res. 1987;7:927–35.
3. Israeli RS, Powell CT, Fair WR, Heston WD. Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen. Cancer Res. 1993;53:227–30.
4. Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res. 1997;3:81–5.
5. Chen Y, Pullambhatla M, Foss CA, Byun Y, Nimmagadda S, Senthamizhchelvan S, Sgouros G, Mease RC, Pomper MG. 2-(3-{1-Carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid, [18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer. Clin Cancer Res. 2011;17:7645–53.